AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2323650
Drug: Induction and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction and consolidation chemotherapy with weekly parenteral vincristine, Adriamycin, l-asparaginase and daily oral prednisone (VAAP), followed by standard CNS prophylaxis. Maintenance therapy for 3 years with daily 6-mercaptopurine, weekly methotrexate and monthly intrathecal therapy, with drug intensification comprising either vincristine, Adriamycin and l-asparaginase (VAA) or cyclophosphamide, vincristine, cytosine arabinoside and prednisone (COAP).
Trial: 27217453
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone agonist (GnRHa) plus norethisterone
Trial: 26711437
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml single use dropper bottle
Trial: 26711437
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g single application squeeze tube containing gel
Trial: 26711437
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml bottle with cotton swab
Trial: 19040739
Drug: Ilioinguinal-iliohypogastric nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilioinguinal-iliohypogastric nerve block (IINB) with 0.5% bupivacaine + 5 mcg/ml epinephrine (Group I, n = 28)
Trial: 10847421
Drug: Enoxaparin (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (0.5, 1.0, and 2.0 mg/kg)
Trial: 10847421
Drug: Dalteparin and
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin and Enoxaparin (therapeutic equivalent doses)
Trial: 1825799
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (administered according to two schedules: early at birth, 3 months, and 6 months; later at 3 months, 4.5 months, and 6 months)
Trial: 1825799
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (unscheduled administration)
Trial: 11219162
Drug: Poliomyelitis vaccine
RxNorm normalized name: Poliomyelitis vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poliomyelitis vaccine
Trial: 27418815
Drug: Glycopyrronium (GLY)
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium (GLY) 50 μg
Trial: 31096036
Drug: Tiotropium (TIO)
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (TIO) 18 μg
Trial: 18165405
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (Vestibulectomy, Biofeedback, Cognitive-behavioral therapy)
Trial: 8504436
Drug: Intravenous 4-aminopyridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 4-aminopyridine (4-AP)
Trial: 8504436
Drug: Oral 4-aminopyridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 4-aminopyridine (4-AP) at maximum daily dosage of 0.5 mg/kg body weight, three times a day for 12 weeks
Trial: 26420970
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (rabeprazole 20 mg and amoxicillin 1 g twice daily for 5 days, followed by rabeprazole 20 mg, clarithromycin 500 mg and metronidazole 500 mg twice daily for 5 days)
Trial: 26420970
Drug: Hybrid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid therapy (rabeprazole 20 mg and amoxicillin 1 g for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days)
Trial: 21708034
Drug: Methylsulfonylmethane (MSM)
DrugBank: Dimethyl sulfone (DB14090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylsulfonylmethane (MSM) 1.125 grams 3 times daily for 12 weeks
Trial: 21708034
Drug: Placebo 3
RxNorm normalized name: placebo 330 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 3 times daily for 12 weeks
Trial: 16817081
Drug: Ethacridine lactate
RxNorm normalized name: ethacridine lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethacridine lactate (10 ml per gestational week, max 200 ml)
Trial: 16817081
Drug: Misoprostol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (200 microg intravaginally, followed by 100 microg oral every 4 hours for 24 hours)
Trial: 16817081
Drug: Misoprostol +
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol + Oxytocin (administered similarly to group III)
Trial: 31697817
Drug: Prophylactic platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic platelet transfusion threshold of 25 × 10^9/L
Trial: 31697817
Drug: Prophylactic platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic platelet transfusion threshold of 50 × 10^9/L
Trial: 21994233
Drug: Infliximab plus
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab plus methotrexate (5 mg/kg at weeks 0, 2, 6, and 14 plus 15 mg/week methotrexate)
Trial: 21994233
Drug: Methotrexate alone
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate alone (15 mg/week)
Trial: 15583700
Drug: sibutramine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sibutramine (10 mg/day)
Trial: 12397571
Drug: Beta-agonist use
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-agonist use
Trial: 10534551
Drug: iloprost (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iloprost (1 ng/kg/min in 6 h i.v. infusion, for 5 consecutive days, 1 week per month)
Trial: 10534551
Drug: low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: low-dose oral cyclosporin A (2.5 mg/kg/day) associated with iloprost
Trial: 2141289
Drug: Orchiectomy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orchiectomy plus dexamethasone 0.5 mg in the morning and 0.3 mg at night
Trial: 2141289
Drug: Orchiectomy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orchiectomy plus cyproterone acetate 100 mg 3 times per day
Trial: 484522
Drug: Pyridoxine 2
RxNorm normalized name: pyridoxine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridoxine 2 mg
Trial: 484522
Drug: Pyridoxine 100
RxNorm normalized name: pyridoxine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridoxine 100 mg
Trial: 484522
Drug: Pyridoxine 100
RxNorm normalized name: pyridoxine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridoxine 100 mg (retreatment)
Trial: 31570495
Drug: Programmed intermittent
RxNorm normalized name: Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed intermittent bolus (PIB) delivery of local anesthetic (10 mL of ropivacaine 0.2% every 2 hours)
Trial: 31570495
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (CI) (5 mL/hour) of local anesthetic
Trial: 30373650
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tongue scraping and aPDT with Bixa orellana extract
Trial: 26488941
Drug: Testosterone (T)
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone (T) - transdermal
Trial: 24500111
Drug: β-alanine (BA)
RxNorm normalized name: Alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-alanine (BA) supplementation (6.4 g day(‐1)) for 4 weeks
Trial: 23151451
Drug: MuStDO5 DNA
RxNorm normalized name: TOXOPLASMA GONDII DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MuStDO5 DNA vaccine with 500 μg of each plasmid and escalating doses of hGM-CSF (0, 20, 100 or 500 μg)
Trial: 19570108
Drug: Combinations of
RxNorm normalized name: Combinations of vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combinations of antipsychotics and mood stabilizers
Trial: 17666974
Drug: Experimental breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental breast cancer treatment
Trial: 15083253
Drug: Oral methylphenidate
RxNorm normalized name: methylphenidate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methylphenidate
Trial: 2517282
Drug: Adjuvant portal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant portal infusion (5‐Fluorouracil 500 mg/m2/d x 7 continuous infusion + Mitomycin‐C 10 mg/m2 on day 1 as a bolus injection)
Trial: 2517282
Drug: Full-dose adjuvant
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose adjuvant chemotherapy (among 195 patients, 85%)
Trial: 2517282
Drug: Adjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant treatment (overall)
Trial: 1166982
Drug: Warfarin (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (daily doses for 21 days)
Trial: 1166982
Drug: Warfarin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin plus rifampin (600 mg a day orally for the last 10 days)
Trial: 31556537
Drug: Naloxone nasal
RxNorm normalized name: naloxone Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone nasal spray 2 mg (20 mg/ml)
Trial: 22541841
Drug: Intravenous naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous naloxone 1 mg
Trial: 22424843
Drug: Adalimumab (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (Group I, n=8) administered from post-operative day 14
Trial: 22424843
Drug: Adalimumab (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (Group II, n=15) administered at 6 months post-operatively after confirmation of endoscopic recurrence despite treatment with azathioprine, infliximab, or 5-ASA
Trial: 19416298
Drug: PCT-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCT-guided treatment in COPD subgroup
Trial: 19416298
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment in COPD subgroup
Trial: 17206943
Drug: budesonide 6
RxNorm normalized name: budesonide 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: budesonide 6 mg and ursodeoxycholic acid 15 mg/kg
Trial: 1910019
Drug: Nitroglycerin ointment
RxNorm normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin ointment placed on arm
Trial: 1910019
Drug: Nitroglycerin ointment
RxNorm normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin ointment placed on chest
Trial: 6351663
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Mr 1268
Trial: 1266667
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg pentazocine
Trial: 31974081
Drug: Intravenous alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase under current local resources
Trial: 31974081
Drug: Intravenous alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase under assumed ideal conditions
Trial: 31974081
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy plus intravenous alteplase under assumed ideal conditions
Trial: 31974081
Drug: Interventional neuroradiologists'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interventional neuroradiologists' decision to refrain from intravenous alteplase under assumed ideal conditions
Trial: 25887932
Drug: Hydros (hyaluronan-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydros (hyaluronan-based hydrogel suspended in hyaluronan solution)
Trial: 25887932
Drug: Hydros-TA (HA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydros-TA (HA plus 10 mg of triamcinolone acetonide)
Trial: 25887932
Drug: Synvisc-One (hylan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synvisc-One (hylan G-F 20)
Trial: 24075893
Drug: γ-T-rich supplementation
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: γ-T-rich supplementation (500 mg γ-T/day)
Trial: 19619148
Drug: Botox (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botox (20 I.E. diluted in 0.5 mL saline)
Trial: 19619148
Drug: Placebo (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.5 mL saline)
Trial: 7921346
Drug: Intravenous alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alcohol infusion (0.5 g ethanol per kg body weight in 15 minutes)
Trial: 2662037
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1 g elemental calcium for 5 days)
Trial: 31960275
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (250 mg magnesium oxide) for 8 weeks
Trial: 27995531
Drug: Subcutaneous IFN‐β‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous IFN‐β‐1a 44 mcg three times a week (group 1)
Trial: 27995531
Drug: Subcutaneous IFN‐β‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous IFN‐β‐1a 44 mcg three times a week plus ethinyl estradiol 40 mcg and desogestrel 125 mcg (group 3)
Trial: 27995531
Drug: Subcutaneous IFN‐β‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous IFN‐β‐1a 44 mcg three times a week plus ethinyl estradiol 20 mcg and desogestrel 150 mcg (group 2)
Trial: 25496007
Drug: Beclabuvir 75
RxNorm normalized name: Beclabuvir
DrugBank: Beclabuvir (DB12225)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Beclabuvir 75 mg plus pegIFN (180 μg) and RBV (1000 mg/day [<75 kg])
Trial: 25496007
Drug: Beclabuvir 150
RxNorm normalized name: Beclabuvir
DrugBank: Beclabuvir (DB12225)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Beclabuvir 150 mg plus pegIFN (180 μg) and RBV (1200 mg/day [≥ 75 kg])
Trial: 23979614
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin (low dose regimen for a Bishop score equal to or more than 7)
Trial: 20977367
Drug: Subconjunctival bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subconjunctival bevacizumab (7.5 mg total: 5 mg/0.2 mL on the day of surgery and 2.5 mg on the fourth day after surgery)
Trial: 20977367
Drug: Balanced salt
RxNorm normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Balanced salt solution (0.2 mL at the end of surgery)
Trial: 19242918
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (n=38) for post-treatment survivors
Trial: 810719
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy (urgent surgical coronary bypass)
Trial: 810719
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy and Surgical therapy
Trial: 31005973
Drug: BCAA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA supplementation (20 g daily for 4 weeks)
Trial: 28891830
Drug: Restrictive fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive fluid infusion (5 mL/kg/h lactated Ringer solution)
Trial: 28891830
Drug: Liberal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal fluid infusion (30 mL/kg/h lactated Ringer solution)
Trial: 25358078
Drug: 50 mcg
RxNorm normalized name: D3, 50 mcg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mcg of sublingual misoprostol
Trial: 25358078
Drug: 25 mcg
RxNorm normalized name: D3, 25 mcg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mcg of vaginal misoprostol
Trial: 21375093
Drug: Subinguinal technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subinguinal technique (5 ml of 1% mepivacaine)
Trial: 21375093
Drug: Nerve-targeting technique
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve-targeting technique (5 ml of 1% mepivacaine)
Trial: 19690428
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy at a dose of 0.066 mg/kg body weight per day
Trial: 15278758
Drug: 10 cc
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 cc of 1% lignocaine + 40 mg of methylprednisolone for the first and second injections
Trial: 15278758
Drug: 10 cc
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 cc of 1% lignocaine + 40 mg of methylprednisolone for the first injection and only 10 cc of 1% lignocaine for the second injection
Trial: 15278758
Drug: only 10
RxNorm normalized name: SYRINGE,ORAL GRADUATED METRIC ONLY 10ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: only 10 cc of 1% lignocaine for the first and second injections
Trial: 28190797
Drug: 60 min
RxNorm normalized name: TITANIUM DIOXIDE 6 g in 100 g / ZINC OXIDE 4.6 g in 100 g TOPICAL STICK [SPF 60 Mineral Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 min physical exercise (PE) at school daily
Trial: 28190797
Drug: 2 units
RxNorm normalized name: Afrezza, 12 units inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 units of 45-min PE weekly (control group)
Trial: 11232683
Drug: EUS-guided celiac
RxNorm normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EUS-guided celiac plexus block with 10 cc bupivacaine (0.25%) and 3 cc (40 mg) triamcinolone injected on each side of the celiac plexus.
Trial: 8270989
Drug: Etoposide at
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide at 20, 25, or 30 mg/m2/d infused continuously for 14 days (336 hours) with a 10-mg/m2 bolus and cisplatin 30 mg/m2 on chemotherapy days 1, 2, and 3
Trial: 8270989
Drug: Etoposide at
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide at maximum-tolerated dose (MTD) of 25 mg/m2/d
Trial: 8270989
Drug: Etoposide with
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide with Css greater than 1 microgram/mL
Trial: 10433587
Drug: Chloroquine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (300 mg weekly) + Primaquine (30 mg daily)
Trial: 2200299
Drug: Lignocaine 20
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 20 mg pretreatment, followed by induction with propofol plus saline 2 ml
Trial: 2200299
Drug: Lignocaine 40
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 40 mg pretreatment, followed by induction with propofol plus saline 2 ml
Trial: 2200299
Drug: Saline pretreatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline pretreatment, followed by induction with propofol plus lignocaine 20 mg
Trial: 2200299
Drug: Saline pretreatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline pretreatment, followed by induction with propofol plus lignocaine 40 mg
Trial: 2200299
Drug: Saline pretreatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline pretreatment, followed by induction with propofol plus saline 2 ml
Trial: 7389253
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg indacrinone alone
Trial: 7389253
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg indacrinone + 2.5 mg amiloride
Trial: 7389253
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg indacrinone + 5 mg amiloride
Trial: 7389253
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg indacrinone
Trial: 27564775
Drug: Thymopentin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin (2 mg per day, 15 days, three courses in total)
Trial: 27564775
Drug: Regular therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular therapy with thymopentin
Trial: 29722166
Drug: SRP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP plus placebo gel
Trial: 15976585
Drug: Lotrafilcon A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotrafilcon A lenses (daily wear)
Trial: 15976585
Drug: Balafilcon A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balafilcon A lenses (daily wear)